التفاصيل البيبلوغرافية
| العنوان: |
Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory |
| المؤلفون: |
Leighl, Natasha B, Akamatsu, Hiroaki, Lim, Sun Min, Cheng, Ying, Minchom, Anna R, Marmarelis, Melina E, Sanborn, Rachel E, Chih-Hsin Yang, James, Liu, Baogang, John, Thomas, Massutí, Bartomeu, Spira, Alexander I, Lee, Se-Hoon, Wang, Jialei, Li, Juan, Liu, Caigang, Novello, Silvia, Kondo, Masashi, Tamiya, Motohiro, Korbenfeld, Ernesto, Moskovitz, Mor, Han, Ji-Youn, Alexander, Mariam, Joshi, Rohit, Felip, Enriqueta, Voon, Pei Jye, Danchaivijitr, Pongwut, Hsu, Ping-Chih, Silva Melo Cruz, Felipe José, Wehler, Thomas, Greillier, Laurent, Teixeira, Encarnação, Nguyen, Danny, Sabari, Joshua K, Qin, Angel, Kowalski, Dariusz, Nahit Şendur, Mehmet Ali, Xie, John, Ghosh, Debopriya, Alhadab, Ali, Haddish-Berhane, Nahor, Clemens, Pamela L, Lorenzini, Patricia, Verheijen, Remy B, Gamil, Mohamed, Bauml, Joshua M, Baig, Mahadi, Passaro, Antonio |
| المصدر: |
J Clin Oncol ; ISSN:1527-7755 |
| بيانات النشر: |
Atypon |
| سنة النشر: |
2024 |
| المجموعة: |
PubMed Central (PMC) |
| الوصف: |
Phase 3 studies of intravenous amivantamab demonstrated efficacy across EGFR-mutated advanced non-small cell lung cancer (NSCLC). A subcutaneous formulation could improve tolerability and reduce administration time while maintaining efficacy. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| العلاقة: |
https://doi.org/10.1200/JCO.24.01001Test; https://pubmed.ncbi.nlm.nih.gov/38857463Test |
| DOI: |
10.1200/JCO.24.01001 |
| الإتاحة: |
https://doi.org/10.1200/JCO.24.01001Test
https://pubmed.ncbi.nlm.nih.gov/38857463Test |
| رقم الانضمام: |
edsbas.8D4F4FC4 |
| قاعدة البيانات: |
BASE |
